Neumann PJ, Greenberg D (2009) Is the United States ready for QALYs? Health Aff
28:1366–1371
Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, Kent DM (2012)
Willingness‐to‐pay for predictive tests with no immediate treatment implications: a survey of
US residents. Health Econ 21(3):238–251
Olson JE, Bielinski SJ, Ryu E, Winkler EM, Takahashi PY, Pathak J, Cerhan JR (2014) Biobanks
and personalized medicine. Clin Genet 86(1):50–55
Payne K, Annemans L (2013) Reflections on market access for personalized medicine: recom-
mendations for Europe. Value Health 16:32–38
Payne K, Shabaruddin FH (2010) Cost-effectiveness analysis in pharmacogenomics. Pharmaco-
genomics 11(5):643–646
Perez EA, Romond EH, Suman VJ (2007) Updated results of the combined analysis of NCCTG
N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with
HER2-positive breast cancer. Proc Am Soc Clin Oncol 25(6s)
Phillips KA, Marshall DA, Haas JS et al (2009) Clinical practice patterns and cost-effectiveness of
HER2 testing strategies in breast cancer patients. Cancer 115:5166–5174
Rawlins MD, Barnett D, Stevens A (2010) Pharmacoeconomics: NICE’s approach to decision
making. Br J Clin Pharmacol 70:346–349
Redekop K, Mladsi D (2013) The faces of personalized medicine: a framework for understanding
its meaning and scope. Value Health 16:4–9
Russell LB (1999) Modelling for cost-effectiveness analysis. Stat Med 18:3235–3244
Shimazawa R, Ikeda M (2013) Are there any differences in the regulations of personalized
medicine among the USA, EU, and Japan? Br J Clin Pharmacol 75:1365–1367
Simon R (2010) Clinical trial designs for evaluating the medical utility of prognostic and
predictive biomarkers in oncology. Pers Med 7:33–47
Simon R, Roychowdhury S (2013) Implementing personalized cancer genomics in clinical trials.
Nat Rev Drug Discov 12(5):358–369
Skedgel C, Rayson D, Younis T (2013) Is adjuvant trastuzumab a cost-effective therapy for
HER-2/neu-positive T1bN0 breast cancer? Ann Oncol 24:1834–1840
Szende A, Oppe M, Devlin N (2007) EQ-5D value sets: inventory, comparative review and user
guide. Springer, Dordrecht
Towse A, Garrison LP (2013) Economic incentives for evidence generation: promoting an
efficient path to personalized medicine. Value Health 16:39–43
Towse A, Ossa D, Veenstra D, Carlson J, Garrison L (2013) Understanding the economic value of
molecular diagnostic tests: case studies and lessons learned. J Pers Med 3(4):288–305
UK Department of Health (2014) Personalised health and care 2020. Policy paperhttps://www.
gov.uk/government/publications/personalised-health-and-care-2020. Accessed 15 Dec 2014
US Food and drugs administration (2014) Paving the way for personalized medicine – FDA’s role
in a new era of medical product development. Policy paperhttp://www.fda.gov/downloads/
ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf. Accessed 5 Jan
2015
Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ (2008) Pharmacoeconomic
evaluations of pharmacogenetic and genomic screening programmes. Pharmacoeconomics
26:569–58710
Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/
College of American Pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
Wong JB (2014) Evidence-based medicine, pharmacogenetics, and antiplatelet therapy decision
making for acute coronary syndrome. Ann Intern Med 160:284–285
Economic Evaluations of Personalized Health Technologies: An Overview of... 135